FDA Panel Rejects Lilly’s Cancer Drug Tested Only in China
FRIDAY, Feb. 11, 2022 (HealthDay News) — A new lung cancer drug that has only been tested in China was soundly rejected by an advisory panel to the U.S. Food and Drug Administration on Thursday. Known as sintilimab, the treatment is a type of immunotherapy that unleashes the immune systemContinue Reading